What is Biotrial?
Founded in 1989, Biotrial operates as a comprehensive service provider for early drug development. The company's expertise spans in vivo pharmacology, early clinical development, and proof of concept studies. With a global footprint including locations in Rennes, Mulhouse (Basel area), London, Montreal, and New Jersey, Biotrial offers a wide array of services. These include Non-Clinical Pharmacology, Phase I trials, Patient Studies, Bioanalysis, ECG & Imaging Core Lab services (specializing in QT/QTc Trials, Psychometric Testing, Imaging, and EEG/PSG Assessment), Oncology research support, Data Management, Biostatistics, Medical Writing, and Quality Assurance & Regulatory Affairs. This integrated approach positions Biotrial as a key partner for pharmaceutical and biotechnology firms navigating the initial phases of therapeutic development.
How much funding has Biotrial raised?
Biotrial has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Biotrial?
The substantial large-scale late-stage funding context suggests Biotrial is poised for significant expansion and enhancement of its service capabilities. This strategic investment will likely fuel advancements in its core offerings, potentially including the expansion of its global facilities, investment in cutting-edge technology for its core lab services, and the broadening of its research support for complex areas like oncology. The company's focus on early development, coupled with its extensive service portfolio, indicates a strategic direction aimed at solidifying its market leadership and supporting a growing pipeline of innovative therapeutics through rigorous scientific validation.
See full Biotrial company page
